Fecal Microbiota Transplantation (FMT) for MDRO UTI
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and impact of fecal microbiota
transplantation (FMT) on the fecal and urine microbiome, urine metabolome, risk of recurrent
urinary tract infection (UTI), and persistent multidrug resistant organism (MDRO)
colonization of patients with a history of recurrent MDRO UTIs. This is an open label phase
1-2 study.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Washington University School of Medicine
Collaborators:
Centers for Disease Control and Prevention Duke University Rebiotix Inc. Rush University University of Pennsylvania